FDA Panel Recommends Moderna mRNA Flu Vaccine for Adults 50 and Older
An FDA advisory panel recommended approval of Moderna's mFlusiva, the first mRNA-based influenza vaccine, for adults ages 50-64 and those 65 and older under specific conditions. In late-stage trials, the vaccine demonstrated 27% greater effectiveness compared to standard flu shots. The panel's recommendation followed a June 18 meeting where FDA officials reviewed the clinical data. Final FDA approval would mark the first mRNA flu vaccine on the market, potentially expanding vaccine options for Medicaid managed care plans covering adult populations.
A new mRNA flu vaccine with higher efficacy could affect MCO vaccine procurement strategies, pharmacy benefit management, and HEDIS flu vaccination rates for Medicare-Medicaid dual eligibles and adult Medicaid populations.
Managed Care · Pharmacy
You might also like